Spots Global Cancer Trial Database for Retreatment With CTL019/CTL119

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Retreatment With CTL019/CTL119

Official Title: Retreatment With CTL019/CTL119 in Patients With Late Relapse of B-Cell Lymphomas

Study ID: NCT04419909

Conditions

Lymphoma, B-Cell

Interventions

CD19 redirected autologous T cells (CTL019 or CTL119 cells)

Study Description

Brief Summary: This research study is designed to evaluate the effects of retreatment with CTL019/CTL119 in patients with late relapse of B-cell lymphomas.

Detailed Description: This is a single arm open label trial that will assess the safety and efficacy of retreatment with CTL019/CTL119 chimeric antigen receptor (CAR) modified T cells in patients who have late relapse of diffuse large B-cell or follicular lymphoma after achieving complete remission from prior CTL019/CTL119 treatment. Patients eligible for this protocol will have been treated initially with CTL019/CTL119 under UPCC13413/NCT02030834, have experienced a durable complete response (defined as ≥ 6 months duration), and have a residual manufactured CTL019/CTL119 product available. This protocol will serve subjects with no available potentially curative treatment options (such as autologous or allogeneic stem cell transplantation) who have a limited prognosis (months to \< 2 year expected survival) with available therapies.